Vigil Neuroscience Inc - Sanofi to Receive an Exclusive Right of First Negotiation for License of Company's Small Molecule Trem2 Agonist Program
賽諾菲安萬特將獲得Vigil Neuroscience Inc.公司小分子Trem2激動劑計劃的獨家首次談判權許可
Vigil Neuroscience Inc - Sanofi to Receive an Exclusive Right of First Negotiation for License of Company's Small Molecule Trem2 Agonist Program
賽諾菲安萬特將獲得Vigil Neuroscience Inc.公司小分子Trem2激動劑計劃的獨家首次談判權許可
譯文內容由第三人軟體翻譯。